The economics
₹749 for TB with drug-resistance. Capped nationwide.
One price, the same on every node, direct to the patient at a fraction of the private market. Affordability is not a discount — it is the product of vertical integration.
Private market
₹1,500–3,000
Private molecular test₹3,000
IVD Yodha · TB + resistance₹749
How the ₹749 cap works
₹99ReagentVertically integrated, made in India
₹350Drug-resistance assayResistance detected at the very first test
₹300Operating + advisoryNode staffing, logistics, QC and therapy guidance
Phase 1 · TB
Grant-funded deployment builds the node footprint and runs TB-with-drug-resistance at the ₹749 nationwide cap — generating an operating surplus on every test.
Seeds the network
Phase 2 · Syndromic
The broader NCDC pathogen panels activate on the same nodes — funded entirely by Phase 1 operating surplus, with zero new grant.
Self-funded expansion
The infrastructure thesis
Vertical integration → a ₹99 reagent → affordability → the market follows. One grant seeds the network; the surplus builds the rest.